Zymeworks Inc.

ZYMENASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
24.19 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
24.25
↗ 0.05 (0.23%)
POST MARKET (AS OF 04:10 PM EDT)
Post Market
AS OF 04:10 PM EDT
24.25
↗ 0.05 (0.23%)
🔴Market: CLOSED

ZYME is currently priced at $24.19. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 17, 2026.

Open?$24.20
High?$24.59
Low?$24.01
Prev. Close?$24.19
Volume?444.7K
Avg. Volume?642.6K
VWAP?$24.30
Rel. Volume?0.69x
Bid / Ask
Bid?$21.06 × 100
Ask?$27.73 × 100
Spread?$6.67
Midpoint?$24.40
Valuation & Ratios
Market Cap?1.8B
Shares Out?73.0M
Float?46.0M
Float %?62.3%
P/E Ratio?N/A
P/B Ratio?10.88
EPS?-$1.40
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
264
Market Cap
1.8B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.zymeworks.com
Listed
2017-04-28
Address
108 PATRIOT DRIVE, SUITE A
MIDDLETOWN, DE 19709
Phone: 302-274-8744
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
6
Momentum?
3
Short Sent.?
34
Piotroski F-Score?2/9Weak
Altman Z-Score?0.51Distress
Confidence?70%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.50%Elevated
Short Interest?4.4M
Days to Cover?6.2
Free Float46.0M
Avg Daily Volume704.8K
Settlement Date2026-06-30
Financial Health
Current Ratio?10.82Strong
Quick Ratio?10.82Strong
Cash Ratio?6.85Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
18
10.88HIGH▾
P/S?
Peers
100
S&P
3
21.90HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-14.3CHEAP▾
EV/Sales?
Peers
100
S&P
3
18.90HIGH▾
Returns & Efficiency
ROE?
S&P
3
-62.7%WEAK▾
ROA?
S&P
3
-21.5%WEAK▾
Cash Flow & Enterprise
FCF?$-77037000
Enterprise Value?$1.5B
Fundamentals ratios updated end of day
MarketsMoversWatchlist